H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6
Ventyx Biosciences' Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold
Express News | Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of Vtx002 (Tamuzimod) in Ulcerative Colitis at Ueg Week 2024
Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Maintains Target Price $10
Oppenheimer analyst Jeff Jones maintains $Ventyx Biosciences(VTYX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 37.9%
LifeSci Capital Maintains Ventyx Biosciences(VTYX.US) With Buy Rating
LifeSci Capital analyst Sam Slutsky maintains $Ventyx Biosciences(VTYX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.5% and a total average return of 8.3%